Plasma perfusion in XXXX .

@entity1 @entity1737 @entity425 @entity7364 @entity134 @entity6815 @entity1282 @entity892 @entity1736
Seven @entity1 with @entity1737 ( @entity1737 ) unresponsive to thymectomy and @entity134 treatment (Osserman group III) underwent plasma perfusion (PP). All @entity1 showed @entity1736 , @entity892 , @entity7364 , @entity1282 , and @entity425 ; five of them had impaired ventilatory function. Separated plasma was perfused onto a column to adsorb anti-AChR-Ab. Each @entity1 received a treatment cycle of six PP sessions. Clinical conditions were assessed before and after the treatment, with evaluation of muscular strength, ventilatory function, and electromyographic testing ( @entity6815 ). Immunologic markers were tested before and after each PP. Clinical improvement in bulbar symptoms and respiratory function was noted in all @entity1 after one to three PP. Limb muscle strength began to improve later. Serum concentration decreased (mean % +/- SD) after each PP:anti-AChR-Ab 36.47 +/- 17.43; IgA 20.44 +/- 11.26; IgG 21.24 +/- 32.56; IgM 23.22 +/- 11.40; C3 36.78 +/- 10.15; C4 42.69 +/- 14.82. In five of seven @entity1 the improvement continues (follow-up 1 to 10 months). In one @entity1 it lasted only 1 month, and in another a relapse occurred after 10 months of benefit, but was successfully reversed by retreatment.
